Orphan medicines: special treatment required?: case study 5: Revolade and treatment of chronic ITP
- Document type
- Case study
- Corporate author(s)
- 2020health (Think tank)
- Date of publication
- 1 November 2012
- Health Services
- Social welfare
- Material type
Download (137KB )
This case study on the drug Revolade and treatment of chronic ITP accompanies a report that examines the evidence to see if there are ways of improving decision making on treatments for people with rare diseases in the NHS. Revolade (eltrombopag) is used in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) and is manufactured by GlaxoSmithKlein (GSK). It’s also used for patients who have had their spleen removed and who do not respond to treatment with medicines such as corticosteroids or immunoglobulins.
Revolade was designated an orphan medicine in 2007. It was approved by European Medicines Agency in 2010.
Related to Health Services
Variation in end of life hospital spending in England: evidence from linked survey and administrative data
Working Paper on healthcare spending
Report on shared measurement in the NHS
Report on human capital in India
Report on data-driven technologies in mental healthcare
Related to 2020health
This report uses literature data, observations and discussions to frame a new approach to understanding the nature and implications of health-system avoidance by individuals who choose to remain ignorant
This report finds that the over 65s made up 17% of the population in 2010, up from 15% in 1985, with projections indicating a rise to 23% by 2035.Exponential growth of an aging population indicates
This report by the Foresight Project aims to ensure that the optical sector is better equipped to understand directions in technology, ocular medical developments and demographics in the years up to 2030.
Current political, economic and social discourse on obesity in the UK illuminates the great complexities and myriad socio-economic considerations that inform people’s health, diets, and health seeking